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Dual-Phase Osteogenic and Vasculogenic
Engineered Tissue for Bone Formation
Rameshwar R. Rao, PhD, Marina L. Vigen, MS, Alexis W. Peterson, BS, David J. Caldwell, MSE,
Andrew J. Putnam, PhD, and Jan P. Stegemann, PhD
Minimally invasive, injectable bone tissue engineering therapies offer the potential to facilitate orthopedic
repair procedures, including in indications where enhanced bone regeneration is needed for complete healing. In
this study, we developed a dual-phase tissue construct consisting of osteogenic (Osteo) and vasculogenic
(Vasculo) components. A modular tissue engineering approach was used to create collagen/fibrin/hydroxyap-
atite (COL/FIB/HA) hydrogel microbeads containing embedded human bone marrow-derived mesenchymal
stem cells (bmMSC). These microbeads were predifferentiated toward the osteogenic lineage in vitro for 14
days, and they were then embedded within a COL/FIB vasculogenic phase containing a coculture of undif-
ferentiated bmMSC and human umbilical vein endothelial cells (HUVEC). In vitro studies demonstrated
homogenous dispersion of microbeads within the outer phase, with endothelial network formation around the
microbeads over 14 days in the coculture conditions. Subcutaneous injection into immunodeficient mice was
used to investigate the ability of dual-phase (Osteo+Vasculo) and control (Osteo, Vasculo, Blank) constructs to
form neovasculature and ectopic bone. Laser Doppler imaging demonstrated blood perfusion through all
constructs at 1, 4, and 8 weeks postimplantation. Histological quantification of total vessel density showed no
significant differences between the conditions. Microcomputed tomography indicated significantly higher ec-
topic bone volume (BV) in the Osteo condition at 4 weeks. At 8 weeks both the Osteo and Blank groups
exhibited higher BV compared to the Vasculo and dual Osteo+Vasculo groups. These data not only show that
osteogenic microbeads can be used to induce ectopic bone formation, but also suggest an inhibitory effect on
BV when undifferentiated bmMSC and HUVEC were included in dual-phase constructs. This work may lead to
improved methods for engineering vascularized bone tissue, and to injectable therapies for the treatment of
orthopedic pathologies in which bone regeneration is delayed or prevented.
Introduction
Amain goal in musculoskeletal tissue engineering isthe regeneration of bone, and in particular to develop
methods for improved healing of recalcitrant bone fractures
and large defects. The treatment of such conditions is a
serious clinical problem, and a significant number of frac-
tures are complicated by delayed and/or incomplete healing.
Many bone tissue engineering strategies aim to recapitulate
the native structure of bone by combining cells, materials,
and signaling molecules in defined architectures. The pri-
mary structural matrix of bone consists of a collagenous
extracellular matrix mineralized by hydroxyapatite (HA).1
However, bone tissue also contains a rich vascular supply,
which is vital to satisfying its high metabolic demand.2
Therefore, both the osseous and the vascular components of
bone are critical to forming functional tissue, and bone
healing requires concomitant development of both compo-
nents. This need for a blood supply to nourish newly forming
bone has motivated a variety of approaches to engineering
vascularized bone tissue.
Controlled delivery of multiple growth factors is one
strategy to achieve regeneration of vascularized bone tissue,
though the results have been mixed. Patel et al. codelivered
bone morphogenetic protein-2 (BMP-2) and vascular en-
dothelial growth factor (VEGF) in an orthotopic rat critical
size defect model.3 The dual (BMP-2 +VEGF) group ex-
hibited significantly higher bone volume (BV) percentage as
measured by microcomputed tomography (mCT) at 4 weeks
compared with the other conditions, but was not statistically
different from the other groups at 12 weeks. In later work by
the same group, the doses of each of the growth factors were
varied in an attempt to reduce BMP-2 concentration while
achieving comparable bone formation, however, the code-
livery of BMP-2 and VEGF did not result in an increase in
bone formation compared to BMP-2 alone.4 In another
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study, Shah et al. evaluated the use of polyelectrolyte films
to control delivery rates of BMP-2 and VEGF and demon-
strated enhanced bone formation measured by mCT in the
dual delivery group, compared with BMP-2 alone at 9
weeks.5 Similarly, genetic modification of bone marrow-
derived mesenchymal stem cells (bmMSC) for the consti-
tutive delivery of both BMP-2 and VEGF demonstrated
enhanced healing in the dual group compared with either
growth factor alone.6 These studies have demonstrated the
potential promise of dual growth factor release, but the ap-
proach is hampered by the complexity of controlling dosing
and obtaining the needed temporal release profile.7–10
Cell-based approaches to vascularized bone tissue engi-
neering also are being pursued.11–13 Numerous studies have
shown that coculture of endothelial cells and osteogenic
cells allows the formation of both vascular networks and
mineralized tissue postimplantation. Kaigler et al. implanted
poly(lactide-co-glycolide) (PLGA) scaffolds containing a
coculture of human microvascular endothelial cells (HMVEC)
and bmMSC into immunodeficient mice and monitored ec-
topic bone formation over 8 weeks.14 Total vasculature was
similar in the implants containing both cell types (bmMSC+
HMVEC) compared to the bmMSC alone, but bone formation
was significantly higher in the dual cell condition compared
with bmMSC alone. Usami et al. also demonstrated ectopic
bone formation through the cotransplantation of endothe-
lial progenitor cells (EPC) and bmMSC on collagen fiber
meshes.15 Both neovasculature and bone formation were sig-
nificantly higher in the bmMSC+EPC group at 12 weeks
postimplantation.
Orthotopic models have also been used to demonstrate
osteogenesis induced by transplant of multiple cell types.
Grellier et al. delivered alginate microspheres seeded with
human umbilical vein endothelial cells (HUVEC) and
bmMSC into a femoral defect model in immunocompro-
mised mice.16 Enhanced bone regeneration was observed in
the dual condition (bmMSC +HUVEC) compared to the
bmMSC group alone. In an attempt to look at the effects of
predifferentiation, Tsigkou et al. first seeded bmMSC on
PLGA scaffolds and then cultured the cell-seeded scaffolds
for 1 week in osteogenic supplemented medium to induce
differentiation.17 The scaffold was then coated with a col-
lagen/fibronectin hydrogel containing bmMSC and HUVEC
and subcutaneously implanted into immunodeficient mice.
Both perfused human vasculature and bone formation were
observed after 8 weeks postimplantation, suggesting an
added benefit to predifferentiating bmMSC prior to im-
plantation in forming vascularized bone tissue.
The goal of this study was to evaluate the effectiveness of
a minimally invasive, injectable, dual-phase tissue engi-
neering approach to the regeneration of vascularized bone,
as shown schematically in Figure 1. Our laboratory has
previously employed modular tissue engineering techniques
to fabricate three-dimensional (3D) cell-seeded hydrogel
‘‘microbeads’’ comprised of physiologically relevant pro-
teins and polysaccharides, and has shown that they can be
used as microenvironments to support osteogenic differen-
tiation of embedded bmMSC.18,19 We have also shown that
composite matrices formed from collagen and fibrin (COL/
FIB) support the formation of vessel-like structures when
seeded with a defined coculture of bmMSC and HUVEC.20
In this work, we have combined osteogenically differenti-
ated bmMSC-seeded COL/FIB/HA microbeads with a COL/
FIB matrix containing both bmMSC and HUVEC. We
performed in vitro studies to examine vessel network for-
mation around the microbeads, and in vivo experiments to
measure ectopic bone formation in a subcutaneous injec-
tion model in immunocompromised mice. This dual-phase
FIG. 1. Schematic of the design and fabrication of dual-phase engineered tissues. Modular microbeads consisting of
bmMSC (green) in a COL/FIB/HA matrix (blue) were fabricated and cultured in osteogenic medium for 14 days. Mi-
crobeads were then combined within a surrounding COL/FIB matrix (pink) containing a coculture of HUVEC (yellow) and
undifferentiated bmMSC (gray). In vitro studies were performed to investigate endothelial network formation around the
osteogenic microbeads. In vivo studies were performed to monitor neovascularization and ectopic bone formation in a
subcutaneous model in the mouse. bmMSC, bone marrow-derived mesenchymal stem cells; COL/FIB/HA, collagen/fibrin/
hydroxyapatite; HUVEC, human umbilical vein endothelial cells. Color images available online at www.liebertpub.com/tea
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microbead-hydrogel approach is initially targeted at non-
load-bearing applications such as tumor resections and other
cavitary defects, though it could be combined with me-
chanical fixation methods for application to load-bearing
defects. The development of injectable and modular meth-
ods to potentiate the formation of vascularized bone would
be an important advance in tissue engineering, and would
have an impact on a variety of clinical pathologies in which
bone healing is delayed or incomplete.
Materials and Methods
Cell culture
Human bmMSC (Lonza, Inc.) were cultured in alpha-
minimum essential media (a-MEM; Life Technologies)
supplemented with 10% bmMSC-qualified fetal bovine
serum (FBS; Life Technologies) and 1% penicillin and
streptomyocin (Life Technologies). The bmMSC in this study
were from a 19-year-old female and were tested for osteo-
genic capacity in culture prior to use. bmMSC were used
between passages 6–8 with media changes every other day.
HUVEC were isolated from umbilical cords as previously
described.20 HUVEC were cultured in endothelial growth
media-2 (EGM-2; Lonza, Inc.) and used between passages
4–5. Culture medium was changed every other day.
Fabrication of osteogenic microbeads
COL/FIB/HA composite microbeads were fabricated as
previously described.19 Briefly, bovine type I COL (MP Bio-
medicals) was dissolved at a concentration of 4.0mg/mL in
0.02N acetic acid. Bovine fibrinogen (FIB; Sigma Aldrich)
was dissolved in serum-free Dulbecco’s modified Eagle’s
medium (DMEM; Thermo Scientific) at 4.0mg/mL clottable
protein. COL and FIB were combined to yield a total protein
concentration of 2.5mg/mL (mass ratio 50/50) and added to a
mixture containing 2% bovine thrombin (1U/mL; Sigma),
1.0mM glyoxal (Sigma), 5% 0.1N NaOH, 10% 5· -concen-
trated DMEM, 10% FBS, and 2.5mg/mL of nano-HA (Sigma)
at 4C. HA was sonicated for 1 h prior to use to maintain
homogenous distribution of the particles after microbead en-
capsulation.21 Cells were directly added into the gel mixture to
guarantee their uniform distribution within the microbeads.
The mixture was then injected into a bath of 100 cSt poly-
dimethylsiloxane (Xiameter; Dow Corning) that was cooled to
0C and stirred at 600 rpm for 5min with a double-bladed
impeller. The temperature was then increased to 37C, in-
ducing gelation of COL and FIB and formation of composite
microbeads with embedded bmMSC. Collection of microbe-
ads from the oil phase was performed by centrifuging the
mixture at 200 g for 5min and washing with phosphate-buff-
ered saline (PBS; Life Technologies) supplemented with
Pluronic L101 (BASF). Microbeads were cultured and main-
tained in a-MEM supplemented with 2.0mg/mL e-amino ca-
proic acid (ACA; Sigma) to prevent fibrinolysis. Media was
changed every other day. Acellular microbeads were stained
with EZBlue Coomasie reagent and visualized with a light
microscope (Olympus America).19 Acellular microbeads were
also labeled with 5mg/mL FITC-fibrinogen (Life Technolo-
gies) at the time of microbead fabrication to visualize disper-
sion within COL/FIB hydrogels.
Osteogenic differentiation of microbeads
Cell-seeded microbeads were induced to differentiate
toward the osteogenic lineage by culturing the microbeads
for 14 days in a-MEM supplemented with 2.0mg/mL ACA,
50 mg/mL ascorbic acid 2-phosphate (Sigma), 10mM b-
glycerophosphate (Sigma), and 100 nM dexamethasone
(Sigma). Microbeads were collected by centrifugation at 200
g for 5min prior to the media change.
Fabrication of vasculogenic matrix
Composite COL/FIB hydrogels were fabricated as pre-
viously described to serve as a vasculogenic surrounding
matrix for the microbeads.20 Both cell-seeded and acellular
microbeads were encapsulated directly into the vasculogenic
gel mixture at a ratio of 1:1 microbead-hydrogel mixture by
centrifuging the microbeads for 5min at 200 g and then
removing the excess media. COL and FIB (total protein
concentration of 2.5mg/mL and a mass ratio of 40/60) were
then added at 4C to 2% bovine thrombin (1U/mL), 5%
0.1N NaOH, 10% 5· -concentrated DMEM, 10% FBS, and
serum-free EGM-2 to bring the final volume to 100%. The
mixture was then transferred into a 24-well plate and allowed
to gel for 30min. Four conditions were used throughout the
study as listed in Table 1. For bmMSC-HUVEC coculture
conditions, both cell types were added into the gel mixture at
300,000 cells/mL (600,000 total cells/mL) at a 1:1 cell ratio.
EGM-2was added on top of the gels and cell-seeded gels were
cultured at 37Cand 5%CO2.Mediawas changed every other
day. A summary of the in vitro cell concentrations and con-
ditions is shown in Table 1.
Immunofluorescent staining
At days 7 and 14, cell-seeded microbeads and hydrogels
were washed twice in PBS for 5min/wash and then fixed in
zinc-buffered formalin (Z-Fix; Anatech) for 10min at 4C.
After two subsequent washes in PBS, embedded cells were
Table 1. Explanation of Microbead and Hydrogel Composition Used for In Vitro Studies
COL/FIB/HA
microbeads COL/FIB hydrogel
Blank Acelluar Acelluar
Vasculo Acellular 3 · 105 bmMSC/mL + 3· 105 HUVEC/mL
Osteo 1 · 106 bmMSC/mL Acellular
Osteo +Vasculo 1 · 106 bmMSC/mL 3 · 105 bmMSC/mL + 3· 105 HUVEC/mL
bmMSC, bone marrow-derived mesenchymal stem cells; COL/FIB/HA, collagen/fibrin/hydroxyapatite; HUVEC, human umbilical vein
endothelial cells.
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permeabilized with 0.5% Triton X-100 (Sigma) in PBS for
20min at room temperature. Gels were then washed again
twice in PBS for 5min/wash, and the appropriate stain was
added at room temperature. Stains were added to 1% bovine
serum albumin (Sigma) in PBS at the appropriate concen-
tration: 165 nM AlexaFluor 488 phalloidin (Life Technolo-
gies), 20 mg/mL rhodamine labeled Ulex Europaeus
Agglutinin I (UEA-1; Vector Laboratories), and 10 nM
fluorescent DAPI (Life Technologies). Gels were then wa-
shed twice in PBS prior to imaging on a confocal micro-
scope (Nikon Instruments, Inc.).
Implantation into subcutaneous site in the mouse
All animal experiments were performed in accordance
with the National Institutes of Health Guidelines and by
following a protocol approved by the University of Mi-
chigan’s Committee on Use and Care of Animals. Male
C.B.-17/SCID mice (Taconic Labs) were anesthetized via
intraperitoneal injection of a drug cocktail containing keta-
mine (95mg/kg; Fort Dodge Animal Health), buprenorphine
(0.059mg/kg; Bedford Laboratories), and xylazine (9.5mg/
kg; Lloyd Laboratories). The injection site on the dorsal
surface of the mouse was then shaved and sterilized with
betadine (Thermo Fisher Scientific) and alcohol prior to
injection. Microbeads were added into the hydrogel mix-
ture at a ratio of 1:1 microbead-hydrogel and the total cell
concentration was increased relative to the in vitro studies
to 10.0 · 106 cells/mL for the bmMSC-HUVEC coculture
conditions (Osteo+Vasculo and Vasculo). A higher cell
concentration was used in this phase of the study to be com-
parable to previous in vivo studies that have demonstrated the
presence of transplanted perfused human vasculature.22,23
Table 2 shows a summary of the cell concentrations used with
each condition. The external hydrogel carrier was used for all
samples. In the Vasculo and Osteo+Vasculo conditions the
external hydrogels contained bmMSC and HUVEC, while in
the Blank and Osteo conditions the external hydrogel was
acellular. Two microbead-hydrogel implants per animal were
subcutaneously injected in the dorsal region. The final volume
of each sample was 300mL. Mice were kept stationary for
2min after injection to allow full gelation of the hydrogel
matrix, and they were then placed in fresh cages. Implanted
samples were visible and palpable immediately after injection,
and remained in place over the 8-week study period.
Laser Doppler perfusion imaging
Blood flow through the implant was imaged noninvasively
using laser Doppler perfusion imaging (LDPI; Perimed
AB).22 After sedation as previously described, mice were
imaged in triplicate. A region of interest was drawn over the
implant area and the mean perfusion through each implant
was calculated. Results are represented as fold change from
perfusion values before implantation (baseline).
lCT imaging
Ectopic bone formation was measured using mCT imag-
ing (mCT100 Scanco Medical). Explanted tissues were first
embedded in 1% agarose and placed in a 34mm diameter
tube and scanned over the entire length of the specimen.
Scan settings were set to voxel size 15mm, 55 kVp, 109mA,
0.5mm AL filter, and integration time 500ms. The thresh-
old used to identify bone was uniformly set at 16% (160 on a
grayscale of 0–1000), based on a baseline value obtained
from HA mineral placed directly on the scanner. Therefore,
all minerals that were observed arose through ectopic min-
eralization. The volume of tissue volume included in the
analysis comprised the entirety of the excised implant in-
cluding the outer COL/FIB hydrogel. Analysis of the BV
(mm3) and tissue mineral density (TMD; mg/cm3) of each
sample was performed using the manufacturer’s software.
Histology
Harvested samples were paraffin embedded, sectioned,
and stained with hematoxylin and eosin and von Kossa at
the Histology Core Facility at the University of Michigan
Dental School. Human cell staining was performed using a
human UEA-1 staining kit per manufacturer’s instructions
(Vector Laboratories). Total vessel density was quantified
by manually quantifying representative images of each
sample in five distinct areas of the implant. Vessels were
defined as structures with lumens containing erythrocytes.
Statistical analysis
All values are presented as mean – standard deviation.
n = 5 samples for in vivo samples. Statistical significance
was set to p< 0.05 and was determined by a one-way
analysis of variance (ANOVA) test with a protected Fisher’s
least significant difference test.
Results
Dispersion of microbeads within COL/FIB hydrogels
Figure 2 shows acellular COL/FIB/HA microbeads in
suspension (Fig. 2A), and fluorescently labeled acellular
COL/FIB/HA microbeads dispersed within COL/FIB hy-
drogels (Fig. 2B, C). Microbeads exhibited a generally
spheroidal morphology immediately after fabrication, and
retained their shape over the 2-week culture period. The
average microbead diameter was approximately 130mm,
and the large majority of microbeads were in the range of
50–250 mm in diameter. Mild aggregation of microbeads
Table 2. Explanation of Microbead and Hydrogel Composition Used for In Vivo Studies
COL/FIB/HA
microbeads COL/FIB hydrogel
Blank Acelluar Acelluar
Vasculo Acelluar 5· 106 bmMSC/mL + 5 · 106 HUVEC/mL
Osteo 1· 106 bmMSC/mL Acellular
Osteo +Vasculo 1· 106 bmMSC/mL 5· 106 bmMSC/mL + 5 · 106 HUVEC/mL
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occurred over time when cultured as high density popula-
tions; however, microbeads were easily dispersed by gentle
pipetting. When embedded in a surrounding COL/FIB hy-
drogel, microbeads were uniformly distributed within the
gel volume (Fig. 2B) and did not aggregate. A 3D recon-
struction of the corresponding Z-stack also showed even
distribution of microbeads in the Z-axis (Fig. 2C).
Formation of endothelial networks around
microbeads in vitro
The generation of vessel-like structures at day 14 around
COL/FIB/HA microbeads embedded in COL/FIB hydrogels
is shown in Figure 3. The locations of microbeads are in-
dicated by ‘‘MB’’ in the image. UEA-1, a human endothelial
cell marker, was used to stain vessel networks. Phalloidin
served to label the actin cytoskeleton of both the bmMSC
and HUVEC, and DAPI showed the nuclei of all cells. Both
the Vasculo and Osteo +Vasculo conditions treatments
showed clear evidence of the formation of vessel-like
structures after 2 weeks in culture, as evidenced by positive
UEA-1 staining of cell networks. Colocalization of bmMSC
and HUVEC was observed in both of these conditions
(positive staining for actin and UEA-1 indicates HUVEC,
whereas positive actin stain not associated with UEA-1 in-
dicates bmMSC). The colocalization of the two cell types
in vitro suggests peri-endothelial interaction between the
two cell types in the composite hydrogel. Neither the Blank
FIG. 2. Light micrograph of (A)
acellular COL/FIB/HA microbe-
ads, and (B) FITC-labeled COL/
FIB/HA microbeads dispersed in a
COL/FIB hydrogel. (C) A 3D re-
construction of the dispersed mi-
crobeads. 3D, three-dimensional.
Color images available online at
www.liebertpub.com/tea
FIG. 3. Vessel-like structure formation around microbeads in vitro. Table 1 explains the sample composition. The Blank
condition consisted of acellular microbeads embedded in an acellular hydrogel. Vasculo samples consisted of acellular
microbeads in a hydrogel containing bmMSC and HUVEC. The Osteo condition consisted of osteogenically differentiated
bmMSC-seeded microbeads embedded in an acellular hydrogel. The Osteo +Vasculo condition consisted of osteogenically
differentiated bmMSC-seeded microbeads embedded in a hydrogel containing bmMSC and HUVEC. Green labeling
(phalloidin) shows the actin cytoskeleton of all cells. Red labeling (UEA-1) is specific for endothelial cells. Blue labeling
(DAPO) shows the nuclei of all cells. ‘‘MB’’ indicates the location of microbeads. Scale bar = 50 mm. UEA-1, Ulex
Europaeus Agglutinin I. Color images available online at www.liebertpub.com/tea
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(acellular) nor the Osteo condition exhibited positive UEA-1
staining or vessel-like structures.
Neovascularization of osteogenic-vasculogenic
constructs in vivo
Subcutaneous injection of osteogenic microbeads sus-
pended in vasculogenic matrix was used to evaluate the de-
gree of both neovascularization and ectopic bone formation
generated by implanted hydrogels. LDPI provided noninva-
sive measurements of blood flow throughout the implant over
the 8-week time course (Fig. 4). A baseline of vascular per-
fusion was taken before implantation and used to normalize
all values at all time points. Perfusion was significantly higher
( p< 0.05) in all conditions at both 1 and 4 weeks post-
implantation, compared with the preimplant baseline. At 8
weeks postimplantation, perfusion values in all conditions
except the Vasculo samples remained significantly higher
than the baseline, indicating constant perfusion through the
implant site. There were no significant differences in perfu-
sion between any of the conditions at any of the time points,
except between the Vasculo and Osteo conditions at 8 weeks.
Histological analysis of explanted tissues was also used to
examine the degree of vascularization and neovessel for-
mation. Vessel density was quantified at both 4 and 8 weeks
and showed no significant differences between any of the
conditions at either time point (Fig. 5). The transplantation
of bmMSC-HUVEC cocultures did not enhance the degree
of vascularization compared to the control Blank (acellular)
condition or to the Osteo alone group. Further, there was
little evidence of positive staining for human UEA-1 in the
Osteo +Vasculo and the Vasculo conditions at 4 weeks (Fig.
6). Degradation of the microbead and hydrogel matrix was
not specifically measured in this study, due to the difficulty
in positively identifying the originally implanted materials
in the histological samples. However, the implants were
visible and palpable throughout the implantation period.
Histology indicated infiltration of the implant sites by host
cells, and the early stages of matrix turnover, concomitant
with vascularization and mineralization.
Ectopic bone formation
mCT was used as a method to nondestructively image and
quantify BV and TMD of explanted tissues (Fig. 7). At 4
FIG. 4. Laser Doppler Perfusion
Imaging. Representative (A, B)
light images of dorsal implants and
(C, D) heat maps representing
perfusion through the implants at 8
weeks. (E) Quantification of mean
perfusion normalized to pre-
implant. *Statistically significant
versus perfusion before implanta-
tion. #Statistically significant ver-
sus Vasculo. $Statistically
significant versus Osteo. Color
images available online at
www.liebertpub.com/tea
FIG. 5. Histology of samples at 4 and 8 weeks post-
implantation. Quantification of erythrocyte-containing ves-
sels (arrows) showed no significant differences between any
of the conditions at either time point (graph). Scale bar =
100mm. Color images available online at www.liebertpub
.com/tea
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weeks, there were no significant differences between the
BV of the Blank, Vasculo, or Osteo +Vasculo conditions.
However, the BV of the Osteo alone group was significantly
higher compared with all other groups. At 8 weeks, both the
Blank and Osteo conditions had significantly higher BV
compared with the Vasculo and Osteo +Vasculo groups.
Evaluation of TMD showed no differences across treatments
at the 4-week time point. At the 8-week time point the Blank
treatment showed significantly higher TMD compared with
the Vasculo or Osteo conditions. Histological analysis and
von Kossa staining confirmed the mCT data (Fig. 8), and
showed the same trends. Positive mineral staining was
evenly distributed throughout the implanted structures in
amounts that correlated with the BV calculations.
Discussion
The goal of this study was to evaluate a dual-phase
microbead-hydrogel system for promoting bone formation.
The osteogenic microbead phase consisted of predifferentiated
bmMSC that were embedded in microscale (50–250mm di-
ameter) COL/FIB/HA modules. The microbeads in turn were
distributed within a 3D vasculogenic matrix consisting of a
COL/FIB hydrogel containing a bmMSC-HUVEC coculture.
Our previous work has demonstrated that microbeads support
osteogenic differentiation of bmMSC,19 and that populations
of microbeads can be collected and injected through a needle
without the loss of cell viability.18 Therefore, microbeads can
be maintained in culture and exposed to desired differentiation
conditions, and they can subsequently be collected and im-
planted without the need to disrupt the cellular microenviron-
ment. Microbeads also can be combined with other types of
biomaterials to createmultiphase constructs.24 In this work, we
homogeneously dispersed osteogenically predifferentiated
microbeads within a COL/FIB composite hydrogel containing
FIG. 6. Staining with human UEA-1 and H&E at 4 weeks.
Arrows indicate corresponding vasculature in the UEA-1 and
H&E slides. Scale bar=200mm. H&E, hematoxylin and eosin.
Color images available online at www.liebertpub.com/tea
FIG. 7. Microcomputed tomog-
raphy analysis of ectopic bone
formation. Images show (A) repre-
sentative 3D volumetric images of
newly formed bone. Graphs show
quantification of (B) total bone
volume and (C) tissue mineral
density. @Statistically significant
versus Blank. #Statistically signifi-
cant versus Vasculo. $Statistically
significant versus Osteo. %Statisti-
cally significant versus Osteo +
Vasculo.
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a coculture of bmMSC-HUVEC that we have previously
shown to support vasculogenesis in vitro.20 The rationale for
combining these phases was to promote simultaneous cellular
osteogenesis and neovascularization to enhance the formation
of new bone. Human cells were used to evaluate their potential
to generate vascularized bone tissue and to maintain clinical
relevance. The overall objective of this work is to develop a
minimally invasive therapy for treating large and recalcitrant
bone defects.
We first investigated vasculogenesis in 3D hydrogel
constructs that contained either acellular or osteogenically
differentiated cell-seeded microbeads in vitro. Robust en-
dothelial cell networks formed in the hydrogel in both
conditions containing HUVEC (Osteo +Vasculo, Vasculo).
Interestingly, we did not observe an inhibitory effect of
including osteogenically differentiated cells into our system
on in vitro vessel formation. Although there are contradic-
tory reports in the literature,25 some studies have observed
that the differentiated state of cocultured bmMSC can in-
fluence vascular network formation by HUVEC.25 In addi-
tion, we did not observe positive staining for endothelial
cell markers in osteogenic microbeads when cultured alone,
in contrast to reports that have suggested that MSC can
differentiate along both osteogenic and vasculogenic cell
lineages.26–29 Taken together, our in vitro data provided
support that osteogenic microbeads could be used in com-
bination with a vasculogenic outer matrix, without impeding
vascular network formation.
We then progressed to a subcutaneous implant model in
the mouse to examine bone and blood vessel formation by
both mono- and dual-phase constructs. The bmMSC in the
osteogenic microbead component were predifferentiated for
2 weeks prior to being combined with an outer hydrogel
containing a combination of undifferentiated bmMSC and
HUVEC immediately prior to injection. Previous studies
have shown that cotransplantation of undifferentiated
bmMSC and HUVEC leads to the generation of vascular
structures containing human cells in this animal model at 1
and 2 weeks.22,23 In these studies, MSC were shown to act
as pericytes in the neovascularization process and their
presence was associated with a more mature and stable
vasculature. The subcutaneous location of the implants used
in this study allowed angiogenesis from surrounding fat and
muscle tissue, thereby generating perfusion of the implant
site. The animal model supported the implantation of two
constructs per animal, and therefore facilitated contralateral
comparisons in this proof-of-concept study.
Noninvasive Doppler imaging showed consistent, above-
baseline levels of construct perfusion regardless of the
treatment condition, with the exception of the purely vas-
culogenic condition at 8 weeks, which showed a significant
decline in perfusion. However, quantification of neovascu-
lature using histology showed no statistically significant
differences between any of the conditions at either time
point. These data suggest that while the constructs were well
perfused, the inclusion of endothelial cells did not improve
vascularization of the implant site. Human endothelial cells
were implanted in this study, however, we observed little
evidence of human UEA-1 staining in the explanted tissues
at 4 or 8 weeks. Previous studies have shown that trans-
planted human cells are present 1 week after implanta-
tion,22,23 suggesting that transplanted cells participate in
generating perfusion, but that they are replaced by host cells
over time. The microbeads used in this study also contained
exogenous HA, the primary mineral component of bone,
which has been shown to have an osteoinductive effect on
bmMSC.30 In addition, HA has shown the ability to promote
sprouting of HUVEC,31,32 and to induce the secretion of
the angiogenic growth factor VEGF when presented to
bmMSC.30,33 The dissolution of HA was not monitored in
this study, but the HA contained within or released from
the microbeads may have provided an angiogenic signal for
the host vasculature to infiltrate the implant and support
bone formation. In this case, the exogenously supplied
HUVEC may not have been needed to achieve perfusion of
the implants.
Previous studies using a variety of experimental systems
have shown that the combination of endothelial cells with
MSC can potentiate bone formation. In vitro studies have
confirmed that coculture of these cell types can achieve re-
ciprocal beneficial effects: endothelial cells can secrete
BMP-2 to serve as osteogenic signal for MSC,14 which can
conversely release VEGF to provide an angiogenic signal for
endothelial cells.34,35 Several studies have shown compara-
ble36 or increased37,38 bone formation with the transplanta-
tion of both cell types in orthotopic bone regeneration
models. Recent studies using ectopic models have yielded
either increased14,17 or equivalent39,40 bone formation in
FIG. 8. von Kossa staining of distributed mineral in im-
plants at 4 and 8 weeks. Black staining indicates minerali-
zation. Scale bar = 1mm. Color images available online at
www.liebertpub.com/tea
DUAL-PHASE ENGINEERED TISSUE FOR BONE FORMATION 537
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f M
ic
hi
ga
n 
e-
jou
rna
l p
ack
ag
e f
rom
 on
lin
e.l
ieb
ert
pu
b.c
om
 at
 12
/08
/17
. F
or 
pe
rso
na
l u
se 
on
ly.
 
the dual cell condition, compared to the osteogenic cell
condition alone. In this study, addition of undifferentiated
bmMSC in combination with HUVEC exhibited a marked
inhibitory effect on ectopic bone formation by osteogenically
differentiated microbeads in vivo. While the mechanism of
action is not evident from these data, the presence of undif-
ferentiated bmMSC in the dual-phase condition may have
resulted in paracrine signals that inhibited bone formation.
The results of our study were clear, but it did not support
our expectation that a dual-phase osteogenic-vasculogenic
tissue construct would enhance bone formation. The com-
plexity of the in vivo environment makes it difficult to draw
strong mechanistic conclusions from this study, however,
modular microbeads represent a leading-edge approach that
combine 3D protein biomaterials and multiple cells types
for multiphase tissue regeneration, and the data we have
presented can guide the work of other groups developing
similar approaches. Additional experiments will help illu-
minate the complex interplay between vasculogenesis and
osteogenesis in the implant environment. In addition, we
note that this study used commercially sourced bmMSC
because they are well characterized for identity and func-
tion, however, our findings need to be validated across a
larger pool of progenitor cell sources to make the results
more generally applicable.
The choice of a subcutaneous ectopic model to examine
proof-of-concept of our dual-phase approach is also relevant
to interpretation of the results, since it is possible that in this
model exogenous cells are not required to achieve neo-
vascularization and mineralization of the implant. Notably,
the Blank (acellular) microbead-hydrogel samples resulted
in a similar degree of bone formation as the Osteo group,
suggesting that the matrix itself may be osteoinductive in this
model, through the recruitment of endogenous cells. There-
fore, an orthotopic model, in which angiogenesis and cellular
recruitment from surrounding tissue is reduced, may be more
appropriate for demonstrating the potential of the dual-phase
tissue approach. In particular, a dual-phase engineered tissue
may be of most value in ischemic bone wounds, in which the
host tissue does not have the ability to regenerate the vas-
culature needed to support bone regeneration. While it is
difficult to create a reliable small animal model of ischemic
bone repair, our approach may show benefit in larger seg-
mental defects, which typically result in nonunion unless a
therapeutic intervention is applied, and where concomitant
regeneration of a vasculature is likely to be more important
for bone formation. Recent studies have suggested that the
processes of neovascularization and bone formation are
coupled, though the relationships are not fully understood.41
In summary, this study has demonstrated the use of an
injectable modular approach that applies COL/FIB/HA
microbeads for orthopedic applications. The microbead
phase generated robust bone formation in an ectopic model.
Contrary to our expectation, the addition of undifferentiated
bmMSC and HUVEC as part of the vasculogenic phase had
an inhibitory effect on bone formation in this model. The
mechanism of inhibition is unclear, but may be related to the
presence of undifferentiated bmMSC in proximity to the
osteogenic phase. Testing of this approach in a nonunion or
ischemic model may illuminate whether endothelial cells
and/or bmMSC can potentiate bone healing in recalcitrant
wounds. This work provides insight into bone formation by
implanted bmMSC, and IT may lead to improved methods
for engineering vascularized bone tissue. The microbead-
hydrogel approach may have utility in treating large cavitary
defects such as tumor resections and avascular necrosis,
where transplantation of cells may be needed to fully re-
generate lost tissue. Such injectable cell-based therapies
would aid in the treatment of a variety of orthopedic pa-
thologies in which bone regeneration is delayed or prevented.
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